The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

Julie T. Kloppenborg; Michael Gamborg; Cilius E. Fonvig; Tenna R.H. Nielsen; Oluf Pedersen; Jesper Johannesen; Torben Hansen; Jens-Christian Holm

doi:10.1111/pedi.12605

The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

Julie T. Kloppenborg, Michael Gamborg, Cilius E. Fonvig, Tenna R.H. Nielsen, Oluf Pedersen, Jesper Johannesen, Torben Hansen, Jens-Christian Holm

4 Citationer (Scopus)

Abstract

OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.

METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.

RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.

CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.

Originalsprog	Engelsk
Tidsskrift	Pediatric Diabetes
Vol/bind	19
Udgave nummer	3
Sider (fra-til)	366-374
Antal sider	9
ISSN	1399-543X
DOI	https://doi.org/10.1111/pedi.12605
Status	Udgivet - 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1111/pedi.12605

Citationsformater

@article{0ed2f446e7c345458b49ae74d7a3195a,

title = "The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment",

abstract = "OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.",

keywords = "Journal Article, Body Mass Index, Glucose Intolerance/blood, Humans, Insulin/blood, Blood Glucose, Male, Prediabetic State/blood, Pediatric Obesity/blood, Young Adult, Weight Loss, Adolescent, Female, Glycated Hemoglobin A/metabolism, C-Peptide/blood, Weight Reduction Programs/statistics & numerical data, Child, Longitudinal Studies, prediabetes, weight loss, children, impaired glucose metabolism, obesity",

author = "Kloppenborg, {Julie T.} and Michael Gamborg and Fonvig, {Cilius E.} and Nielsen, {Tenna R.H.} and Oluf Pedersen and Jesper Johannesen and Torben Hansen and Jens-Christian Holm",

note = "Funding information The Novo Nordisk Foundation, Grant/Award number: NNF15OC0016544; Novo Nordisk, Grant/Award number: unrestricted educational grant; The Danish Innovation Foundation, Grant/Award number: 0603‐00457B; The Region Zealand Health Scientifics Research Foundation",

year = "2018",

doi = "10.1111/pedi.12605",

language = "English",

volume = "19",

pages = "366--374",

journal = "Pediatric Diabetes",

issn = "1399-543X",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

AU - Kloppenborg, Julie T.

AU - Gamborg, Michael

AU - Fonvig, Cilius E.

AU - Nielsen, Tenna R.H.

AU - Pedersen, Oluf

AU - Johannesen, Jesper

AU - Hansen, Torben

AU - Holm, Jens-Christian

N1 - Funding information The Novo Nordisk Foundation, Grant/Award number: NNF15OC0016544; Novo Nordisk, Grant/Award number: unrestricted educational grant; The Danish Innovation Foundation, Grant/Award number: 0603‐00457B; The Region Zealand Health Scientifics Research Foundation

PY - 2018

Y1 - 2018

N2 - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.

AB - OBJECTIVE: To investigate whether children and adolescents exhibiting an impaired glucose metabolism are more obese at treatment entry and less likely to reduce their degree of obesity during treatment.METHODS: The present study is a longitudinal observational study, including children and adolescents from the Children's Obesity Clinic, Holbaek, Denmark. Anthropometrics, pubertal development, socioeconomic status (SES), and fasting concentrations of plasma glucose, serum insulin, serum C-peptide, and whole blood glycosylated hemoglobin (HbA1c) were collected at treatment entry and at follow-up. Proxies of Homeostasis Model Assessment 2-insulin sensitivity (HOMA2-IS) and Homeostasis Model Assessment 2-β-cell function (HOMA2-B) were calculated with the Homeostasis Model Assessment 2 program.RESULTS: In total, 569 (333 boys) patients, median 11.5 years of age (range 6-22 years), and median body mass index (BMI) z-score 2.94 (range 1.34-5.54) were included. The mean BMI z-score reduction was 0.31 (±0.46) after 13 months (range 6-18) of treatment. At treatment entry, patients with impaired estimates of glucose metabolism were more obese than normoglycemic patients. Baseline concentration of C-peptide was associated with a lower weight loss during treatment in girls (P = .02). Reduction in the insulin concentrations was associated with reduction in BMI z-score in both sexes (P < .0001, P = .0005). During treatment, values of glucose, HbA1c, HOMA2-IS, and HOMA2-B did not change or impact the treatment outcome, regardless of age, sex, SES, or degree of obesity at treatment entry.CONCLUSION: The capability to reduce weight during multidisciplinary treatment in children and adolescents with overweight/obesity is not influenced by an impaired glucose metabolism at study entry or during the course of treatment.

KW - Journal Article

KW - Body Mass Index

KW - Glucose Intolerance/blood

KW - Humans

KW - Insulin/blood

KW - Blood Glucose

KW - Male

KW - Prediabetic State/blood

KW - Pediatric Obesity/blood

KW - Young Adult

KW - Weight Loss

KW - Adolescent

KW - Female

KW - Glycated Hemoglobin A/metabolism

KW - C-Peptide/blood

KW - Weight Reduction Programs/statistics & numerical data

KW - Child

KW - Longitudinal Studies

KW - prediabetes

KW - weight loss

KW - children

KW - impaired glucose metabolism

KW - obesity

U2 - 10.1111/pedi.12605

DO - 10.1111/pedi.12605

M3 - Journal article

C2 - 29159854

SN - 1399-543X

VL - 19

SP - 366

EP - 374

JO - Pediatric Diabetes

JF - Pediatric Diabetes

IS - 3

ER -

The effect of impaired glucose metabolism on weight loss in multidisciplinary childhood obesity treatment

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater